MAP2K7 and metastatic melanoma: Despite prior expectations that, by apparently overcoming oncogene-induced intratumoral immune suppression,24 25 concurrent BRAF/MEK inhibitor therapy would augment adoptive cell therapies27 we did not discern any positive effect of BRAF/MEK inhibition (by dabrafenib and trametinib) on GD2-CAR-T cell expansion or persistence in metastatic melanoma patients.